Takeda Pharmaceutical Co. $TAK Stake Reduced by First Trust Advisors LP

First Trust Advisors LP decreased its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 3.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,517,439 shares of the company’s stock after selling 84,369 shares during the period. First Trust Advisors LP owned approximately 0.08% of Takeda Pharmaceutical worth $36,855,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in TAK. EverSource Wealth Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 5.3% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 16,927 shares of the company’s stock worth $248,000 after purchasing an additional 850 shares in the last quarter. U.S. Capital Wealth Advisors LLC boosted its holdings in Takeda Pharmaceutical by 8.9% during the third quarter. U.S. Capital Wealth Advisors LLC now owns 12,991 shares of the company’s stock worth $190,000 after buying an additional 1,064 shares in the last quarter. Signaturefd LLC boosted its holdings in Takeda Pharmaceutical by 1.4% during the third quarter. Signaturefd LLC now owns 80,783 shares of the company’s stock worth $1,183,000 after buying an additional 1,152 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after buying an additional 1,292 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of Takeda Pharmaceutical by 24.5% in the third quarter. Farther Finance Advisors LLC now owns 7,001 shares of the company’s stock valued at $102,000 after buying an additional 1,378 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on TAK. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Saturday, January 31st. Morgan Stanley started coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Down 1.9%

Shares of NYSE:TAK opened at $17.77 on Friday. The firm has a 50 day simple moving average of $17.39 and a 200 day simple moving average of $15.53. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.82. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.65 and a current ratio of 1.19. The company has a market cap of $56.55 billion, a PE ratio of 74.05 and a beta of 0.01.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Thursday, January 29th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.40. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. The company had revenue of $6.75 billion for the quarter, compared to the consensus estimate of $7.81 billion. As a group, research analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.